Kinnate Biopharma News

KNTEDelisted Stock  USD 2.96  0.27  8.36%   
About 61% of Kinnate Biopharma's investor base is looking to short. The analysis of current outlook of investing in Kinnate Biopharma suggests that many traders are alarmed regarding Kinnate Biopharma's prospects. The current market sentiment, together with Kinnate Biopharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Kinnate Biopharma stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Disposition of 520711 shares by Foresite Capital Management Iv, Llc of Kinnate BiopharmaInc at 2.587...
Google News at Macroaxis
over six months ago at news.google.com         
Kinnate Biopharma Inc. Receives Average Recommendation of Hold from Analysts - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Kinnate Biopharma Inc. Sees Significant Decline in Short Interest - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Citigroup Inc. Buys 419795 Shares of Kinnate Biopharma Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender...
Google News at Macroaxis
over six months ago at news.google.com         
Kinnate Biopharma Inc. Given Consensus Recommendation of Hold by Brokerages - MarketBeat
Google News at Macroaxis
over six months ago at news.google.com         
Kinnate Biopharma Inc. Stake Increased by Citigroup Inc. - MarketBeat
Google News at Macroaxis
over six months ago at benzinga.com         
Disposition of 558 shares by Williams Richard Thomas of Kinnate BiopharmaInc at 2.59 subject to Rule...
benzinga news
over six months ago at benzinga.com         
SHAREHOLDER ALERT Levi Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of th...
benzinga news
over six months ago at finance.yahoo.com         
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Labo...
Yahoo News
over six months ago at seekingalpha.com         
Kinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratories
seekingalpha News
over six months ago at marketwatch.com         
Kinnate Biopharma Sells Exarafenib Assets to Pierre Fabre Labs
marketwatch News
over six months ago at zacks.com         
Kinnate Biopharma Inc. Upgraded to Buy What Does It Mean for the Stock?
zacks News
over six months ago at news.google.com         
Kinnate Biopharma Price Target Raised to 2.59 - Defense World
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Stifel Nicolaus Boosts Kinnate Biopharma Price Target to 2.59
news
Far too much social signal, news, headlines, and media speculation about Kinnate Biopharma that are available to investors today. That information is available publicly through Kinnate media outlets and privately through word of mouth or via Kinnate internal channels. However, regardless of the origin, that massive amount of Kinnate data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kinnate Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kinnate Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kinnate Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kinnate Biopharma alpha.

Kinnate Biopharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
06/01/2023
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like